Bioresorbable polymeric stents: current status and future promise

被引:60
作者
Eberhart, RC
Su, SH
Nguyen, KT
Zilberman, M
Tang, LP
Nelson, KD
Frenkel, P
机构
[1] Univ Texas, SW Med Ctr, Dept Surg, Dallas, TX 75390 USA
[2] Univ Texas, SW Med Ctr, Biomed Engn Program, Dallas, TX USA
[3] Univ Texas, Arlington, TX 76019 USA
[4] Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX USA
关键词
stent; bioresorbable polymer; drug delivery; gene therapy; in-stent restenosis;
D O I
10.1163/156856203321478838
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Metal stents and, more recently, polymer-coated metal stents are used to stabilize dissections, eliminate vessel recoil, and guide remodeling after balloon angioplasty and other treatments for arterial disease. Bioresorbable polymeric stents are being developed to improve the biocompatibility and the drug reservoir capacity of metal stents, and to offer a transient alternative to the permanent metallic stent implant. Following a brief review of metal stent technology, the emerging class of expandable, bioresorbable polymeric stents is described, with emphasis on developments in the authors' laboratory.
引用
收藏
页码:299 / 312
页数:14
相关论文
共 104 条
  • [1] Aggarwal R. K., 1997, Journal of the American College of Cardiology, V29, p353A
  • [2] Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor antibody
    Aggarwal, RK
    Ireland, DC
    Azrin, MA
    Ezekowitz, MD
    deBono, DP
    Gershlick, AH
    [J]. CIRCULATION, 1996, 94 (12) : 3311 - 3317
  • [3] DEFORMATION CHARACTERISTICS OF A BIOABSORBABLE INTRAVASCULAR STENT
    AGRAWAL, CM
    CLARK, HG
    [J]. INVESTIGATIVE RADIOLOGY, 1992, 27 (12) : 1020 - 1024
  • [4] Coexpression of guanylate kinase with thymidine kinase enhances prodrug cell killing in vitro and suppresses vascular smooth muscle cell proliferation in vivo
    Akyürek, LM
    Nallamshetty, S
    Aoki, K
    San, H
    Yang, ZY
    Nabel, GJ
    Nabel, EG
    [J]. MOLECULAR THERAPY, 2001, 3 (05) : 779 - 786
  • [5] Inhibition of neointima formation after experimental coronary artery stenting -: A new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost
    Alt, E
    Haehnel, I
    Beilharz, C
    Prietzel, K
    Preter, D
    Stemberger, A
    Fliedner, T
    Erhardt, W
    Schömig, A
    [J]. CIRCULATION, 2000, 101 (12) : 1453 - 1458
  • [6] Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients with coronary artery disease
    Amoroso, G
    van Boven, AJ
    van Veldhuisen, DJ
    Tio, RA
    Baljé-Volkers, CP
    Petronio, AS
    van Oeveren, W
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2001, 38 (04) : 633 - 641
  • [7] Balter S, 1998, CATHETER CARDIO DIAG, V45, P292
  • [8] Nitinol - Its use in vascular surgery and other applications
    Barras, CDJ
    Myers, KA
    [J]. EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2000, 19 (06) : 564 - 569
  • [9] Stenting for ischemic heart disease
    Belli, G
    Ellis, SG
    Topol, EJ
    [J]. PROGRESS IN CARDIOVASCULAR DISEASES, 1997, 40 (02) : 159 - 182
  • [10] Biocompatibility aspects of new stent technology
    Bertrand, OF
    Sipehia, R
    Mongrain, R
    Rodés, JR
    Tardif, JC
    Bilodeau, L
    Côté, G
    Bourassa, MG
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (03) : 562 - 571